Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Submitted by
admin
on September 6, 2013 - 10:31am
Source:
Seeking Alpha
News Tags:
Teva
Rexahn
RX-3117
Headline:
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble
Do Not Allow Advertisers to Use My Personal information
